Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 8/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.31 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3243363 | 0.86 | ACHE (0.43) | MELKDYRK1ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL3245515 | 0.83 | CCR5 (0.42) | MELKDYRK1ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL3238195 | 0.80 | L3MBTL1 (0.36) | MELKDYRK1ACYP1A2HSD17B10 | |
| SCHEMBL3239897 | 0.80 | HDAC1 (0.36) | MELKDYRK1APDE5A | |
| SCHEMBL3237558 | 0.80 | MELK (0.35) | MELKDYRK1A | |
| SCHEMBL3241352 | 0.80 | MAPK1 (0.43) | — | |
| SCHEMBL3241193 | 0.79 | KCNH2 (0.37) | DYRK1A | |
| SCHEMBL3240374 | 0.79 | KMT2A (0.39) | CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3240022 | 0.79 | L3MBTL1 (0.46) | DYRK1A | |
| SCHEMBL3242256 | 0.78 | PYCR1 (0.35) | MELKDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009131958-A2 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING TRIAZINE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2009-10-29 | — | — | WO | claimed |
| US-20090264433-A1 | Compounds, Compositions and Methods Comprising Triazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | claimed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| WO-2009131958-A2 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING TRIAZINE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264433-A1 | Compounds, Compositions and Methods Comprising Triazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264433-A1 | Compounds, Compositions and Methods Comprising Triazine Derivatives | CFTR, PKD1, PKD2 | MELK 3208/4885DYRK1A 3098/4885PDE5A 259/4885 |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | MELK 2699/4885DYRK1A 2818/4885PDE5A 1336/4885 |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | MELK 2699/4885DYRK1A 2818/4885PDE5A 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.